9 European Sleep Tech Startups Worth Watching in 2026
European Sleep Tech Startups in 2026 Are Rewriting How Sleep Apnea Gets Caught and Treated
From radar sensors beside the bed to AI-scored home tests, a new generation of European companies is rewriting how snoring and sleep apnea get caught and treated.
Why European sleep tech startups in 2026 matter
European sleep tech startups in 2026 are shifting sleep apnea care from a single overnight hospital test into a continuous, at-home process that starts with a wearable and ends with a treatment plan. Obstructive sleep apnea (OSA) is a condition where the throat muscles relax during sleep and repeatedly narrow or block the airway, cutting off breathing for seconds at a time. It affects an estimated 175 million people across the continent, yet the vast majority never receive a formal diagnosis.
That gap is exactly what this new wave of companies is built to close. Some focus on catching the first warning signs without a single wire touching the skin, an approach covered in more depth in our guide to contactless radar sleep sensors. Others focus on turning a night of raw data into a clinical-grade diagnosis, or on keeping patients engaged with treatment once they have one. This roundup organizes nine genuinely European companies by where they sit on that journey, grounded in the epidemiology behind why the market exists at all.
Unlike many global "sleep tech" lists that blend non-European brands with EU medical-device makers, every company profiled here is headquartered in Europe and operates, at least in part, under EU or UK medical-device rules. That distinction matters, because a wellness gadget and a regulated diagnostic tool are held to very different standards of accuracy.
- European sleep tech startups in 2026 span three stages: home screening, clinical diagnosis, and therapy or compliance support.
- Roughly 80-90% of OSA cases in Europe remain undiagnosed, which is the core problem these companies are trying to solve.
The scale of sleep apnea in Europe
Obstructive sleep apnea is one of the costliest undiagnosed conditions in European healthcare. A 2026 epidemiology analysis published in the European Journal of Neurology estimated that sleep disorders cost high-income Europe roughly €422.9 billion a year, with OSA alone responsible for about €184 billion of that total, the single largest share of any sleep disorder studied (Bassetti, Welter et al., 2026). A separate 16-country study presented at the European Respiratory Society Congress put the number of affected adults at around 175 million, with roughly 90 million living with moderate-to-severe disease (Benjafield et al., ERS, 2018).
Those numbers explain why investors and public health systems alike are paying attention. A condition this large, this underdiagnosed, and this expensive is precisely the kind of gap that consumer-facing sleep tech startups are chasing, because even a modest improvement in early detection translates into a very large addressable market.
How these European sleep tech startups map to your sleep journey
Most people's path through sleep apnea care follows a predictable sequence: suspect a problem, get screened, get formally diagnosed, then start and stick with treatment. Understanding which stage a given startup addresses makes it much easier to judge whether its product is actually useful to you, or simply an interesting gadget.
| Stage | Question it answers | Example companies | Typical device type |
|---|---|---|---|
| 1. Screening | Should I worry about my breathing at night? | Sunrise, Withings, Somnofy | Contactless or wearable sensor |
| 2. Diagnosis | Do I actually have OSA, and how severe is it? | Acurable, Onera Health, Hapni | Clinical-grade home sleep test |
| 3. Therapy & compliance | How do I treat it and stay consistent? | Dreem Health, Nyxo, Pulsetto | Coaching platform or adjunct device |
- No single startup covers the entire journey; most specialize in one of three stages.
- A screening result is a prompt to get tested, not a diagnosis on its own.
Stage 1: At-home screening and detection
Screening tools are designed to flag risk quickly, often without a prescription, so people know whether a proper test is worth pursuing. Several European companies are pushing this category toward zero-wire, zero-effort monitoring.
1Sunrise (Belgium)
Sunrise makes a small sensor that clips to the chin overnight and tracks tiny mandibular (jaw) movements linked to breathing effort and sleep stages. The data syncs to a smartphone app and is designed to flag possible OSA and snoring patterns without a bulky headset or chest strap.
2Withings (France)
Not a scrappy newcomer, but this Paris-based company keeps pushing contactless sensing forward with its under-mattress Sleep Analyzer, which tracks breathing disturbances and snoring without any wearable at all. It is a useful benchmark for the smaller EU startups racing to match its scale.
3Somnofy by VitalThings (Norway)
Somnofy uses low-power radar, placed beside the bed rather than on the body, to estimate breathing rate, movement, and sleep stages. It is one of a growing number of Nordic sensor companies exploring radar as an alternative to wearables for long-term home monitoring.
Stage 2: Getting an accurate diagnosis
A home sleep apnea test works by recording breathing effort, airflow, oxygen saturation, and sometimes body position overnight, then scoring that data against clinical thresholds to estimate an apnea-hypopnea index (AHI). For decades, doctors leaned on screening tools like the Berlin Questionnaire, a short symptom survey, to decide who needed a full test; these newer devices aim to make the test itself far more accessible than a hospital sleep lab.
4Acurable (United Kingdom)
Acurable's AcuPebble is a small, CE-marked acoustic sensor worn near the throat that records breathing sounds and movement overnight. It has been used in NHS-linked pilot programs as a lower-cost alternative to overnight lab-based polysomnography for diagnosing OSA.
5Onera Health (Netherlands)
Onera builds a modular system of wireless, disposable patches that replace the tangle of wires used in a traditional sleep lab. The patches capture polysomnography-grade signals at home, and the results are read using automated scoring, the same category of technology covered in our piece on AI-scored home sleep tests.
6Hapni (France)
Hapni, which has raised approximately €2 million, focuses specifically on apnea and snoring detection paired with a coaching app that helps users understand their results and follow through on next steps, rather than leaving them with a raw data file.
- Home tests can now approach lab-grade accuracy for many patients, cutting the wait for a diagnosis from months to days.
- An AHI score from any of these devices should still be reviewed by a qualified clinician before treatment begins.
Stage 3: Therapy, compliance, and staying asleep
Getting a diagnosis solves only half the problem; the harder challenge is sticking with treatment for years. This stage is where European sleep tech startups are experimenting with coaching, telemedicine, and adjunct tools to keep people engaged.
7Dreem Health (France)
Dreem started as a consumer EEG headband for tracking brain activity during sleep and has since pivoted toward clinical and pharmaceutical research tools, supporting hospitals and drug trials that need objective sleep-stage data rather than self-reported diaries.
8Nyxo (Finland)
Nyxo pairs with existing wearables and rings to translate sleep data into personalized coaching, nudging users toward habits, such as consistent bedtimes and reduced evening light exposure, that support whatever therapy their doctor has prescribed.
9Pulsetto (Lithuania)
Pulsetto makes a wearable vagus nerve stimulation device marketed for stress reduction and relaxation before bed. It is not an apnea treatment, but it illustrates the growing interest in adjunct wellness tools that sit alongside, not instead of, prescribed sleep apnea therapy.
Several of these companies now connect to online sleep clinics that let patients review results and adjust treatment with a clinician remotely, closing the loop between data collection and actual medical guidance.
CE mark vs FDA clearance: the EU regulatory reality
A CE mark means a device has been assessed against EU Medical Device Regulation (MDR 2017/745) requirements for safety and performance; it is the European equivalent of, but legally separate from, FDA clearance in the United States. Nearly every company in this list is CE-marked or working toward it, since that is the minimum bar for selling a medical device anywhere in the EU. The stricter MDR framework, fully phased in over the past few years, has actually pushed some smaller startups to slow their launches while they gather more clinical evidence, which is a reasonable trade-off for patient safety even if it frustrates investors chasing a fast 2026 rollout.
Several of these startups, including Acurable and Onera, have also pursued or obtained FDA clearance, a separate regulatory pathway with its own clinical-evidence requirements for diagnostic claims. For UK-based companies, a separate UKCA marking now applies alongside or instead of the CE mark following Brexit, adding another layer of complexity that most patient-facing coverage of this sector overlooks entirely.
- A CE mark confirms basic safety and performance, not that a device is as accurate as a hospital sleep lab.
- Always check whether a product is CE-marked as a medical device, not merely a general wellness product, before trusting its output for a diagnosis.
What to do after a positive screening result
A positive result from any of these tools is a starting point, not a finish line. Moderate-to-severe OSA, generally an AHI of 15 or higher, still requires a full clinical work-up and, in most cases, CPAP (continuous positive airway pressure) therapy or another treatment prescribed by a sleep specialist. That part of the pathway has not changed.
For snorers and people with mild-to-moderate OSA specifically, that low adherence rate is why many look for a simpler first step before, or alongside, a full CPAP setup. A CE-certified Class I nasal stent such as Back2Sleep is one option this group tries: a soft silicone insert worn inside the nostrils that keeps the nasal airway open overnight, with no electricity, no tubing, and no mask to tolerate. Starter kits with four sizes are sold directly across the EU without a prescription, and they are not a substitute for CPAP in moderate-to-severe cases, which still need proper clinical treatment.
- A wearable's "high risk" flag should always lead to a clinician-reviewed diagnostic test, not self-treatment.
- Mild OSA and simple snoring have the lowest CPAP adherence and the widest range of lower-friction alternatives worth discussing with a doctor.
The bottom line on European sleep tech startups in 2026
European sleep tech startups in 2026 are not competing to build one all-in-one device; they are dividing up a patient journey that used to run entirely through overcrowded hospital sleep labs. Screening tools from companies like Sunrise, Withings, and Somnofy are pulling risk detection into ordinary bedrooms. Diagnostic players like Acurable, Onera Health, and Hapni are compressing weeks of waiting into a single night at home. And compliance-focused platforms like Dreem Health, Nyxo, and Pulsetto are trying to solve the much harder problem of keeping people on treatment for the long haul.
The throughline across all nine is accessibility: cheaper, faster, and less intimidating than a traditional overnight lab study. Whichever stage of that journey you're at, the fastest way to a good outcome is still the same as it has always been, get a proper diagnosis, understand your severity, and choose a treatment path, whether that is CPAP, an oral appliance, or a lower-friction option for milder cases, that you can actually stick with.
No single company on this list can yet claim to be the definitive leader; the sector is still too young and too fragmented across screening, diagnosis, and compliance for one clear winner to have emerged. What is clear is that the direction of travel, more testing at home, faster results, and more support for sticking with treatment, is good news for the tens of millions of Europeans currently living with undiagnosed sleep apnea.
What Back2Sleep Users Say
Frequently Asked Questions
What is the biggest sleep tech startup in Europe right now?
There is no single agreed 'biggest' European sleep tech startup, since companies compete in different niches, screening, diagnosis, or compliance, and none has independently verified market-leading status. Established names like Withings have the largest consumer reach, while newer diagnostic-focused startups such as Onera Health and Acurable are gaining traction in clinical settings.
Can a wearable device actually diagnose obstructive sleep apnea at home?
Some CE-marked home sleep test devices, including Acurable's AcuPebble and Onera Health's patch system, can produce clinical-grade data doctors use to help diagnose OSA. General consumer wearables and smartwatches can only flag risk; a formal diagnosis still requires a validated medical device and review by a qualified clinician.
Are European sleep-tech medical devices CE-marked or FDA-cleared?
Most credible European sleep tech companies hold a CE mark, the EU's baseline safety and performance certification under Medical Device Regulation. Some, including Acurable and Onera Health, have also pursued FDA clearance as an additional regulatory pathway. UK-based devices may carry a separate UKCA mark following Brexit, alongside or instead of the CE mark.
What are the alternatives to CPAP for mild obstructive sleep apnea?
For mild OSA and simple snoring, options to discuss with a doctor can include weight management, positional therapy, oral appliances, and mechanical nasal devices such as internal nasal stents. These alternatives are generally not appropriate for moderate-to-severe OSA, where CPAP or another clinician-prescribed therapy remains the standard of care.
Can my Apple Watch detect sleep apnea like these startups do?
Recent Apple Watch models include a breathing disturbances feature that can flag signs consistent with possible sleep apnea over a 30-day period. It is a screening notification, not a diagnosis; a positive alert should be followed by a proper CE-marked home sleep test or a lab-based study.
What is the Berlin Questionnaire and do these startups replace it?
The Berlin Questionnaire is a validated symptom survey doctors use to estimate someone's risk of obstructive sleep apnea before ordering a test. Newer sensor-based startups complement rather than replace it, often pairing a quick risk questionnaire with objective overnight data for a fuller picture.
How does a home sleep apnea test work?
A home sleep apnea test uses a small wearable or patch to record breathing effort, airflow, oxygen levels, and sometimes body position overnight. The data is then scored, often with AI-assisted algorithms, to estimate an apnea-hypopnea index, which a clinician reviews to confirm diagnosis and severity.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.